168 related articles for article (PubMed ID: 33775995)
1. Cytokine Release Syndrome Induced by Immune-checkpoint Inhibitor Therapy for Non-small-cell Lung Cancer.
Yomota M; Mirokuji K; Sakaguchi M; Kitahara Y; Chin F; Setoguchi K; Hosomi Y
Intern Med; 2021 Nov; 60(21):3459-3462. PubMed ID: 33775995
[TBL] [Abstract][Full Text] [Related]
2. Cytokine release syndrome complicated with severe rashes induced by nivolumab plus ipilimumab therapy in a patient with non-small cell lung cancer: A case report.
Tsutsui T; Hata K; Kawaguchi M; Kobayashi H; Kakizaki Y; Miyashita Y
Thorac Cancer; 2023 Aug; 14(23):2310-2313. PubMed ID: 37381088
[TBL] [Abstract][Full Text] [Related]
3. Cytokine Release Syndrome in Cancer Patients Receiving Immune Checkpoint Inhibitors: A Case Series of 25 Patients and Review of the Literature.
Tay SH; Toh MMX; Thian YL; Vellayappan BA; Fairhurst AM; Chan YH; Aminkeng F; Bharwani LD; Huang Y; Mak A; Wong ASC
Front Immunol; 2022; 13():807050. PubMed ID: 35154124
[TBL] [Abstract][Full Text] [Related]
4. Severe Cytokine Release Syndrome and Immune Effector Cell-associated Neurotoxicity Syndrome in a Man Receiving Immune Checkpoint Inhibitors for Lung Cancer.
Tanaka T; Taoka M; Makimoto G; Ninomiya K; Higo H; Fujii M; Ichihara E; Ohashi K; Hotta K; Tabata M; Maeda Y
Intern Med; 2024 May; 63(9):1261-1267. PubMed ID: 37722894
[TBL] [Abstract][Full Text] [Related]
5. Delayed immune-related neutropenia with hepatitis by pembrolizumab.
Nakako S; Nakashima Y; Okamura H; Tani Y; Ueda T; Makuuchi Y; Kuno M; Takakuwa T; Nishimoto M; Koh H; Nakamae H; Hino M
Immunotherapy; 2022 Feb; 14(2):101-105. PubMed ID: 34758635
[TBL] [Abstract][Full Text] [Related]
6. Systemic inflammatory syndromes as life-threatening side effects of immune checkpoint inhibitors: case report and systematic review of the literature.
Liu LL; Skribek M; Harmenberg U; Gerling M
J Immunother Cancer; 2023 Mar; 11(3):. PubMed ID: 36878533
[TBL] [Abstract][Full Text] [Related]
7. Treatment- and immune-related adverse events of immune checkpoint inhibitors in advanced lung cancer.
Shao J; Wang C; Ren P; Jiang Y; Tian P; Li W
Biosci Rep; 2020 May; 40(5):. PubMed ID: 32315071
[TBL] [Abstract][Full Text] [Related]
8. Fatal cytokine-release syndrome in a patient receiving toripalimab: a case report.
Zhou Y; Zheng GH; Li N; Liu JJ; Wang XH; Li YF
Immunotherapy; 2023 Jun; 15(9):641-645. PubMed ID: 37139989
[TBL] [Abstract][Full Text] [Related]
9. Immune checkpoint inhibitor-related chronic pneumonitis: a case report and literature review.
Yuan-Di Wang ; Yuan S; Wen C; Ji Z; Xiang B; Wang B; Zhang Z
Immunotherapy; 2023 Oct; 15(14):1117-1123. PubMed ID: 37431609
[TBL] [Abstract][Full Text] [Related]
10. Immune checkpoint inhibitor-induced autoimmune encephalitis in metastatic squamous cell lung cancer.
Wang J; Zheng Q; Chen J
Immunotherapy; 2023 Apr; 15(6):409-416. PubMed ID: 36950965
[TBL] [Abstract][Full Text] [Related]
11. Immune-related organizing pneumonitis in non-small cell lung cancer receiving PD-1 inhibitor treatment: A case report and literature review.
Yin B; Xiao J; Li J; Liu X; Wang J
J Cancer Res Ther; 2020; 16(7):1555-1559. PubMed ID: 33565499
[TBL] [Abstract][Full Text] [Related]
12. A case of cytokine release syndrome accompanied with COVID-19 infection during treatment with immune checkpoint inhibitors for non-small cell lung cancer.
Murata D; Azuma K; Tokisawa S; Tokito T; Hoshino T
Thorac Cancer; 2022 Oct; 13(20):2911-2914. PubMed ID: 36073307
[TBL] [Abstract][Full Text] [Related]
13. Delayed cytokine release syndrome after neoadjuvant nivolumab: a case report and literature review.
Ciner AT; Hochster HS; August DA; Carpizo DR; Spencer KR
Immunotherapy; 2021 Sep; 13(13):1071-1078. PubMed ID: 34287029
[TBL] [Abstract][Full Text] [Related]
14. Pembrolizumab-induced cytokine release syndrome in a patient with metastatic lung adenocarcinoma: a case report.
Sackstein P; Zaemes J; Kim C
J Immunother Cancer; 2021 Jul; 9(7):. PubMed ID: 34330765
[TBL] [Abstract][Full Text] [Related]
15. Impact of interstitial lung disease associated with immune checkpoint inhibitors on prognosis in patients with non-small-cell lung cancer.
Yamagata A; Yokoyama T; Fukuda Y; Ishida T
Cancer Chemother Pharmacol; 2021 Feb; 87(2):251-258. PubMed ID: 33394102
[TBL] [Abstract][Full Text] [Related]
16. Hemophagocytic lymphohistiocytosis (HLH) and cytokine release syndrome (CRS) in a patient with oncogene-addicted metastatic non-small cell lung cancer (NSCLC) following combination chemotherapy-immunotherapy.
Heynemann S; Vanguru V; Adelstein S; Kao S
Asia Pac J Clin Oncol; 2024 Apr; 20(2):315-318. PubMed ID: 36562695
[TBL] [Abstract][Full Text] [Related]
17. Bloodborne Cytokines for Predicting Clinical Benefits and Immune-Related Adverse Events in Advanced Non-Small Cell Lung Cancer Treated With Anti-Programmed Cell Death 1 Inhibitors.
Oyanagi J; Koh Y; Sato K; Teraoka S; Tokudome N; Hayata A; Akamatsu H; Ozawa Y; Nakanishi M; Ueda H; Yamamoto N
Clin Lung Cancer; 2021 Nov; 22(6):e833-e841. PubMed ID: 34049821
[TBL] [Abstract][Full Text] [Related]
18. Timing of resumption of immune checkpoint inhibitor therapy after successful control of immune-related adverse events in seven advanced non-small cell lung cancer patients.
Kashiwabara K; Fujii S; Tsumura S; Sakamoto K
Anticancer Drugs; 2020 Sep; 31(8):872-875. PubMed ID: 32796406
[TBL] [Abstract][Full Text] [Related]
19. Cytokine release syndrome induced by immune checkpoint inhibitor treatment for uterine cervical cancer recurrence: A case report.
Sekimata M; Kinjo Y; Tohyama A; Murakami M; Hashiwaki S; Saito Y; Higami S; Hagimoto M; Taketomi R; Hoshino K; Harada H; Ueda T; Kurita T; Matsuura Y; Yoshino K
Oncol Lett; 2024 Jul; 28(1):331. PubMed ID: 38807673
[TBL] [Abstract][Full Text] [Related]
20. Association of tumour burden with the efficacy of programmed cell death-1/programmed cell death ligand-1 inhibitors for treatment-naïve advanced non-small-cell lung cancer.
Suzuki S; Haratani K; Hayashi H; Chiba Y; Tanizaki J; Kato R; Mitani S; Kawanaka Y; Kurosaki T; Hasegawa Y; Okabe T; Tanaka K; Akashi Y; Ozaki T; Nishio K; Ito A; Nakagawa K
Eur J Cancer; 2022 Jan; 161():44-54. PubMed ID: 34922263
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
